Live Feeds
● LIVE Updated 1h ago · 13 sources tracked

Kodiak Sciences soars as Zenkuda, tabirafusp-ted hit primary endpoints in phase III wet AMD trial

Kodiak Sciences shares rose over 162% by midday Monday after two drug candidates, Zenkuda and tabirafusp-ted, met primary endpoints in the Phase III DAYBREAK trial for wet age-related macular degeneration. The therapies demonstrated statistical equivalence and non-inferiority to aflibercept. Zenkuda, also known as tarcocimab tedromer, showed vision gains and retinal drying with a p-value of 0.0007. Notably, 54% of patients in the trial reached a six-month dosing interval. The results have led to bullish analyst revisions and substantial insider buying, though some valuation risks persist.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (13)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Zenkuda and tabirafusp-ted met primary endpoints in the Phase III DAYBREAK trial for wet age-related macular degeneration.
  • ✓ Zenkuda, also known as tarcocimab tedromer, achieved a p-value of 0.0007.
  • ✓ Both therapies demonstrated non-inferiority and statistical equivalence to aflibercept.
  • ✓ 54% of patients in the vision trial went six months between eye treatments.
🛡️ Source Corroboration: 13 independent reporting domains (100% confidence) ⏱ Read time: ~2 min

What changed

Kodiak Sciences reported that Zenkuda and tabirafusp-ted met primary endpoints in the Phase III DAYBREAK study.

Live updates

  1. Kodiak Sciences stock surges after Phase III wet AMD trial success

    Kodiak Sciences shares rose over 162% by midday Monday after two drug candidates, Zenkuda and tabirafusp-ted, met primary endpoints in the Phase III DAYBREAK trial for wet age-related macular degeneration. The therapies demonstrated statistical equivalence and non-inferiority to aflibercept. Zenkuda, also known as tarcocimab tedromer, showed vision gains and retinal drying with a p-value of 0.0007. Notably, 54% of patients in the trial reached a six-month dosing interval. The results have led to bullish analyst revisions and substantial insider buying, though some valuation risks persist.

    Why it matters

    Wet AMD is a retinal disease requiring frequent eye injections. Zenkuda and tabirafusp-ted are designed to compete with Eylea, the current market standard. Success in this trial allows the company to move toward a Biologics License Application filing.

    What is confirmed

    • Zenkuda and tabirafusp-ted met primary endpoints in the Phase III DAYBREAK trial for wet age-related macular degeneration.
    • Zenkuda, also known as tarcocimab tedromer, achieved a p-value of 0.0007.
    • Both therapies demonstrated non-inferiority and statistical equivalence to aflibercept.
    • 54% of patients in the vision trial went six months between eye treatments.
    • Kodiak Sciences shares increased by over 162% by midday Monday.

    Still unconfirmed

    • Kodiak Sciences targets a Q4 BLA filing.
    • Martin Shkreli claims the results still suck.

    What to watch next

    • Submission of the Biologics License Application (BLA)
    • FDA review and approval decision for Zenkuda and tabirafusp-ted
    Sources used for this update (17)
    1. Forbes — Kodiak Sciences Up 150% At Opening Bell After Drugs Pass Key Trial
    2. Yahoo Finance — Kodiak Sciences soars as Zenkuda, tabirafusp-ted hit primary endpoints in phase III wet AMD trial
    3. FirstWord — Kodiak surges on Phase III victory for Eylea rival in wet AMD
    4. Yahoo Finance — KOD Stock Cracks September’s Top 5 Biotech Gainers On Eye Drug Win — But ‘Pharma Bro’ Shkreli Says It ‘Still Sucks’
    5. stocktitan.net — In a vision trial, 54% of patients went six months between eye treatments
    6. www.marketbeat.com — KOD News Today | Why did Kodiak Sciences stock go up today? $KOD
    7. finance.yahoo.com — Kodiak Sciences soars as Zenkuda, tabirafusp-ted hit primary ...
    8. www.prnewswire.com — Zenkuda and tabirafusp-ted Meet Primary Endpoints in Pivotal ...
    9. www.proactiveinvestors.com — Kodiak Sciences soars as Zenkuda, tabirafusp-ted hit primary ...
    10. allsci.com — Kodiak’s Zenkuda and tabirafusp-ted meet Phase III endpoints ...
    11. trial.medpath.com — Kodiak's Zenkuda and tabirafusp-ted hit primary endpoints in ...
    12. retinalphysician.com — DAYBREAK Meets Primary Endpoint in Wet AMD | Retinal Physician
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community